Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27039764 | 0.98 | CTNNB1 (0.48) | CTNNB1WNT3AP2RX7GSK3BPTPN1 | |
| SCHEMBL16601146 | 0.76 | PTPN1 (0.45) | CTNNB1WNT3AGSK3BPTPN1 | |
| SCHEMBL17224134 | 0.76 | GSK3B (0.45) | GSK3BPTPN1 | |
| SCHEMBL6317653 | 0.75 | CTNNB1 (0.50) | CTNNB1WNT3AP2RX7GSK3BCES2 | |
| SCHEMBL8744790 | 0.75 | P2RX7 (0.54) | CTNNB1WNT3AP2RX7CES2CES1 | |
| SCHEMBL882968 | 0.75 | CTNNB1 (0.50) | CTNNB1WNT3AP2RX7KMT2A | |
| Hydrochloric Acid SCHEMBL2819700 | 0.73 | P2RX7 (0.52) | CTNNB1WNT3AP2RX7CES2CES1 | |
| SCHEMBL3741436 | 0.73 | CTNNB1 (0.48) | CTNNB1WNT3AGSK3BPTPN1KMT2A | |
| SCHEMBL29603588 | 0.73 | CTNNB1 (0.48) | CTNNB1WNT3AGSK3BPTPN1KMT2A | |
| SCHEMBL17820081 | 0.73 | ALOX15 (0.44) | GSK3BPTPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220324860-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-13 | — | — | US | disclosed |
| CN-113993583-A | Substituted pyrazolo [4,3-b ] pyridines and their use as modulators of the GLUN2B receptor | 詹森药业有限公司 | 2022-01-28 | — | — | CN | disclosed |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-02 | — | — | US | disclosed |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-02 | — | — | US | disclosed |
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| WO-2020249791-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2013-08-15 | — | — | US | disclosed |
| WO-2012061019-A2 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | CTNNB1 1988/4885WNT3A 3923/4885P2RX7 2389/4885 |
| US-20200392130-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN3B, GRIN3A | CTNNB1 2148/4885WNT3A 2060/4885P2RX7 70/4885 |
| US-20130210804-A1 | TRICYCLIC MGLUR5 RECEPTOR MODULATORS | GRM5, GRM1, GRM2 | CTNNB1 4833/4885WNT3A 4615/4885P2RX7 406/4885 |
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, PAH, INHA | CTNNB1 315/4885WNT3A 554/4885P2RX7 1420/4885 |
| US-20220324860-A1 | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN3B, GRIN3A | CTNNB1 2148/4885WNT3A 2060/4885P2RX7 70/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | CTNNB1 1988/4885WNT3A 3923/4885P2RX7 2389/4885 |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | GRIN2B, GRIN3B, GRIN3A | CTNNB1 2148/4885WNT3A 2060/4885P2RX7 70/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | CTNNB1 1988/4885WNT3A 3923/4885P2RX7 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.